RESEARKA

Several methodological questions complicate the interpretation and synthesis of Glycation AGEs clinical evidence. The heterogeneity of AGE measurement approaches — including SAF, circulating AGE levels, HGI, and dietary AGE intake estimation — makes cross-study comparison challenging, as these modalities may capture distinct aspects of glycation burden (Li 2026). Endpoint selection across trials and observational studies spans a wide range from surrogate biomarkers (e.g., inflammatory markers, skin elasticity measures) to hard clinical outcomes (e.g., all-cause mortality, cardiovascular events), and it remains unclear whether improvements in Glycation AGEs surrogates translate to meaningful clinical benefit, echoing the general concern that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). Treatment duration in existing RCTs has been short, typically ranging from weeks to a few months, which may be insufficient to capture the slow kinetics of AGE accumulation and AGE-mediated tissue damage that unfold over years to decades. The concurrent use of background medications and lifestyle interventions in many trials further obscures the independent contribution of AGE-directed strategies; for example, the Ozdemir trial involved concurrent caloric restriction alongside AGE modification, making it difficult to isolate the Glycation AGEs-specific treatment effect (Ozdemir 2025). Population heterogeneity also presents a challenge: the evidence base includes healthy volunteers, patients with type 2 diabetes, individuals on peritoneal dialysis, critically ill patients, and PCOS cohorts, and the clinical significance of Glycation AGEs may differ substantially across these contexts. The observation that HGI predicts mortality in one direction in atrial fibrillation but in the opposite direction in hemorrhagic stroke underscores the context-dependency of Glycation AGEs biomarkers and cautions against overgeneralizing from any single clinical setting (Wu 2025; Zeng 2026). Finally, attrition and adherence in long-duration dietary interventions — where typical attrition rates in older-adult trials approach 20% (Schulz 2010) — represent practical barriers to conducting the definitive large-scale RCTs that the field requires to move from mechanistic plausibility to evidence-based clinical recommendations.

Citation Support

• source_1 Movahedian 2025
• source_2 Kopytek 2025
• source_3 Chang 2025
• source_4 Wu 2025
• source_5 Li 2026